Related Experiment Video
Updated: Apr 19, 2026
06:26
Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
Published on: January 24, 2025
2.1K
The new biologics in pregnancy
Summary
New biological agents are increasingly prescribed to women of reproductive age, leading to more pregnancies exposed to these drugs. This review examines their use, safety, and research in pregnant women.
Area of Science:
- Reproductive medicine and pharmacology
- Immunology and drug development
Background:
- An increasing number of women of reproductive age are prescribed novel biological agents.
- This trend results in a growing number of pregnancies exposed to these medications.
- Understanding the implications for maternal and fetal health is crucial.
Purpose of the Study:
- To identify new biological agents (biologics) and their common indications.
- To review current usage patterns of biologics in pregnant women.
- To discuss concerns and existing knowledge regarding the reproductive safety of these agents.
Main Methods:
- Literature review of current and emerging biological therapies.
- Analysis of data on biologic use during pregnancy.
- Synthesis of information on reproductive safety profiles and research gaps.
Main Results:
- Identifies specific classes of new biologics and their therapeutic targets.
- Summarizes current clinical approaches to using biologics in pregnant populations.
- Highlights key safety considerations and available data on reproductive outcomes.
Conclusions:
- Growing biologic use in women of childbearing age necessitates careful consideration during pregnancy.
- Further research is essential to fully elucidate the reproductive safety of these agents.
- Informed clinical decision-making requires ongoing evaluation of evidence and patient-specific factors.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
367
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
367
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
824
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
824
01:22Development of Immunocompetence
1.2K
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
1.2K
01:07Teratogenicity
4.6K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.6K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
1.0K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
1.0K
01:21Intrauterine Drug Delivery Systems
155
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
155